A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
Trial details
- Registry ID
- NCT06697223
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.NCT06697223 | Cerus Corporation | Phase 2 | Completed | 2025-06-02Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |